Stay updated with breaking news from Jonathane Rosenberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-TYRA-300 is the first oral, FGFR3-selective agent to be evaluated in the clinic- -Conference call and webcast today, Nov. 29th, at 9:00 am ET- CARLSBAD, Calif., Nov. 29, 2022 /PRNewswire/ -- Tyra...
Enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma may provide disease control with manageable safety.
Enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma may provide disease control with manageable safety.
'Encouraging activity' with enfortumab vedotin-pembrolizumab in patients with high unmet need
– Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab –– Data highlighted in late-breaking presentation at the European Society for Medical Oncology (ESMO) Congress 2022 –BOTHELL, Wash. & TOKYO & RAHWAY, N.J.--(BU...